Method for culturing patient-derived cancer cells expedites treatment decisions for bladder cancer
- Summary
- Michael M. Shen, Ph.D.
- Technology Benefits
- Ability to establish a cell line from only a small tumor sampleHigh efficiency rate (89%) with rapid cell growth timeframeCell lines can remain in culture for an extended period of timeCell lines can be frozen for long-term storage and thawed at a later date with normal growthPatient-derived cell lines would be specific to each bladder cancer case for personalized therapyPatent information:Patent PendingTech Ventures Reference: IR CU14280
- Technology Application
- Modeling the efficacy of intravesical therapy agents to determine course of action in treating bladder cancer patientsUse for drug therapy development to treat bladder cancerUse for pathophysiology studies of bladder cancerModeling diseases related to unregulated cell growthCreation of a tissue library of cancerous tissue for research purposes (bladder cancer or otherwise)
- Detailed Technology Description
- Michael M. Shen, Ph.D.
- *Abstract
-
None
- *Inquiry
- Peter GolikovColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- CU14280
- *Principal Investigator
-
- *Publications
- Barlow L, Chua CW, Lei M, DeCastro J, Badani K, Benson M, McKiernan J, Shen M. Poster: An individualized approach to bladder cancer treatment using patient-derived cell lines to predict response to chemotherapeutic agents. American Association for Cancer Research (AACR) Annual Meeting, San Diego, April 2014.
- Country/Region
- USA
For more information, please click Here
